SCHEDULE: Orca Capital AG Discloses 9.9% Stake in Co-Diagnostics

Orca Capital AG has filed an amended Schedule 13G, reporting a 9.9% beneficial ownership stake in Co-Diagnostics, Inc.

Summary

• Orca Capital AG beneficially owns 6,001,135 shares of Co-Diagnostics, Inc. common stock.
• This ownership represents 9.9% of the company's outstanding common stock.
• The calculation is based on 60,144,855 shares of Common Stock outstanding immediately after the completion of the Issuer's registered offering.
• Orca Capital AG also holds 362,500 shares of Common Stock issuable upon the exercise of pre-funded warrants.
• The exercise of these pre-funded warrants is subject to a 9.99% blocker, preventing Orca Capital AG from beneficially owning more than 9.99% of Co-Diagnostics' outstanding shares.

Sentiment

Score: 6

Explanation: The filing is primarily informational, disclosing a significant institutional ownership stake. The maintenance of a near-10% position by Orca Capital AG can be interpreted as a moderately positive signal of investor confidence, despite the 9.99% blocker on warrant exercise.

Positives

• A significant institutional investor, Orca Capital AG, maintains a substantial 9.9% stake in Co-Diagnostics, indicating continued confidence in the company.

Negatives

• NA

Risks

• The 9.99% blocker on pre-funded warrants limits Orca Capital AG's ability to increase its beneficial ownership beyond this threshold through warrant exercise, potentially capping its influence or investment flexibility.

Future Outlook

NA

Management Comments

• Orca Capital AG certifies that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of Co-Diagnostics, Inc., nor in connection with any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

This filing reflects an institutional investor's significant stake in a company, which is a common occurrence in the public markets. It does not provide specific insights into broader industry trends for diagnostics or biotechnology beyond the investor's confidence in Co-Diagnostics.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake by Orca Capital AG may positively influence investor sentiment and perception of Co-Diagnostics' stability and potential.
• Management: Awareness of a large institutional holder may influence strategic decisions, though Orca Capital AG has certified it does not intend to influence control.

Key Dates

Recommendation

This Schedule 13G filing primarily serves as a disclosure of a significant beneficial ownership stake by Orca Capital AG in Co-Diagnostics, Inc. While the maintenance of a near-10% position by an institutional investor can be seen as a positive signal of confidence, the filing itself does not provide new financial performance data, strategic updates, or operational insights that would warrant a 'buy' or 'sell' recommendation. Therefore, a 'hold' recommendation is appropriate, acknowledging the informational value of the filing without suggesting a change in investment thesis based solely on this ownership disclosure.

Keywords

Co-Diagnostics, Orca Capital AG, Schedule 13G, Beneficial Ownership, Common Stock, Pre-funded Warrants, Institutional Investor, SEC Filing